• Celebrex
• Alternative
• Attorney
• Black Box
• Bleeding
• Cancer
• Cardiac Problems
• Claim
• Class Action
• Danger
• Dosage
• Heart
• Heart Disease
• Information
• Label Change
• Lawsuit
• Legal
• Litigation
• Problem
• Reaction
• Safety
• Side Effects
• Stroke
• Warning
• Withdrawal
• Contact a Lawyer

Find a Lawyer in Your State

Need Help?

• Accutane®
• Cerebral Palsy
• Darvocet®
• Denture Cream
• Depuy ASR™ Hip Implant
• Fosamax® Femur Fracture
• MiniMed Insulin Pump
• Multaq®
• Nephrogenic Systemic Fibrosis
• Paxil® Birth Defects
• Propecia®
• Shoulder Pain Pump
• Topamax®
• Truck Accident Lawyer
• Wellbutrin®
• Yaz® Birth Control

Consumer rights groups and medical experts across the nation have argued for the inclusion of a Celebrex black box warning on all product information for this medication, the only COX-2 pain killer remaining on the market. The Celebrex black box sought was to include strong warnings, the strongest the FDA can order short of a drug recall, about the serious risks of cardiovascular side effects associated with Celebrex.

In 2004 the results of a Pfizer-sponsored clinical trial indicated that use of Celebrex at 400 milligrams per day could more than double a patient’s risk of suffering a heart attack or stroke. The study also found that patients taking 800 milligrams more than tripled their risk of suffering a life-threatening cardiovascular event. Similar findings were also discovered in Bextra and Vioxx studies, and these drugs were subsequently removed from the drug market.

Bextra, Vioxx, and Celebrex are all similar COX-2 non-steroidal anti-inflammatory drugs used to treat the chronic pain associated with rheumatoid and osteoarthritis and other pain conditions. Vioxx was first to be pulled off the market in September 2004 after studies found that patients taking this drug for 18 months doubled their risk of heart attack and stroke. Bextra was recalled in 2005 for unacceptable cardiovascular risks and serious skin conditions.

Though Celebrex has been linked to similar risks, the FDA has allowed this COX-2 painkiller to remain on the market, in part because of its additional benefits in the treatment of colon polyps (FAP). Instead of a recall, the FDA ordered the addition of a Celebrex black box warning to all product labeling to inform consumers about serious cardiovascular risks. The Celebrex black box is the most potent warning that the FDA can order and requires a black box detailing the risks in bold type on all written information and a verbal explanation of the showcased risks on all Celebrex commercials.

In August 2005, the FDA sent out a mixed message by approving Celebrex for a new use while simultaneously issuing a Celebrex black box warning about the serious risks associated with cardiovascular injuries. The FDA approved Celebrex for the treatment of pain associated with ankylosing spondylitis, or arthritis of the spine. The FDA also issued the Celebrex black box, advising of patient risks and providing treatment recommendations.

The Celebrex black box warning recommends that patients be prescribed the lowest dose medication possible to be used for the shortest duration possible. The warning also states that patients should not be given Celebrex for the treatment of pain following heart bypass surgery. The Celebrex black box warns patients of increase cardiovascular and gastrointestinal risks. All NSAIDs, except aspirin, now contain warning similar to the Celebrex black box warning regarding these adverse drug events.

If you would like to learn more about the Celebrex black box or have been injured by this medication, please contact us to speak with a qualified and experienced attorney.

"Celebrex safety concerns reaps benefits for alternative painkillers"

After COX-2 painkillers – Vioxx, Celebrex and Bextra- came under scrutiny when cardiovascular risks were associated to the drugs some drugmakers saw this as an opportunity to try to capitalize on the events.

Vioxx went off the market in Se...

» Read More

"Is pharmaceutical advertising too aggressive?"

Merck & Co. and Pfizer Inc. have been criticized for their aggressive marketing campaigns for its COX-2 drugs, putting scrutiny on pharmaceutical advertising as a whole. Between December 2003 and November 2004, pharmaceutical ad spending increased 30...

» Read More

"COX-2 safety questions far from answered"

A three-day FDA Advisory Committee meeting has wrapped, but the COX-2 drugs controversy is still not resolved. Although the panel of government medical experts advised keeping the drugs, including Pfizer Inc.’s Celebrex and Bextra, on the market, new...

» Read More

• Accutane® |
• Acetaminophen |
• Actavis Information |
• Actos® |
• Amiodarone |
• Trasylol® - Aprotinin Injection |
• Avandia® |
• Baycol® |
• Bextra® |
• Botox |
• Byetta® |
• Celebrex |
• Cellcept |
• Chantix® |
• Cipro Side Effects |
• Crestor |
• Darvocet |
• Darvon® |
• Defective Drug FAQ |
• Common Defective Drugs |
• Depakote® |
• Drug Company Information |
• Defective Drug Side Effects |
• Duragesic Patch |
• Exjade |
• Fentanyl |
• Fen Phen |
• Fleet Phospho Soda |
• Fluoroquinolone Antibiotics |
• Fosamax |
• Gadolinium |
• Gardasil |
• Gleevec |
• Heparin |
• Humira and Remicade |
• Hydroquinone |
• Hydroxycut |
• Januvia® and Janumet® Information |
• Kava Kava |
• Ketek |
• Lariam |
• Levaquin |
• Lupron (Leuprolide) |
• Meridia |
• Multaq® |
• Naproxen (Aleve) |
• Natrecor |
• Neurontin |
• Nexium® (Esomeprazole Magnesium) Heartburn Relief |
• NuvaRing® |
• Ocella Information |
• Osteonecrosis and Fosamax |
• Oxycontin |
• Palladone |
• Paxil |
• Permax |
• Plavix |
• PPA |
• Pradaxa® |
• Prevacid® |
• Prilosec® |
• Procrit |
• Propecia® (Finasteride) |
• Propoxyphene |
• Protonix® |
• Protopic |
• Prozac |
• What is Quinine? |
• Rapamune® Lawyer |
• Raptiva |
• Reglan |
• Remicade Lawsuit |
• Rezulin |
• Risperdal |
• Ritalin |
• Serevent |
• Seroquel |
• Serzone |
• Tequin |
• Thimerosal |
• Topamax® (Topiramate) |
• Viagra® |
• Wellbutrin® |
• Xenical |
• Yasmin® |
• Yaz Birth Control Lawyer |
• Zelnorm |
• Zocor® Medication Information |
• Zoloft |
• Zyprexa |